---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-125852"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:57:38.477453+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TransCode receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until June 2023

## Summary
- Nasdaq notified TransCode on Dec 9, 2022 that common stock failed minimum $1.00 bid price for 30 consecutive days through Dec 8.
- Company has until June 7, 2023 to regain compliance; bid price must close at $1.00+ for 10 consecutive business days.
- If not cured, Company may qualify for additional 180-day period or face delisting; possible reverse stock split considered.
- No immediate delisting; Company intends to monitor and explore options to regain compliance.

## SEC filing metadata
- accession: 0001104659-22-125852
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465922125852/0001104659-22-125852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465922125852/tm2232381d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-125852
- JSON: https://secwatch.observer/filing/0001104659-22-125852.json
- Plain text: https://secwatch.observer/filing/0001104659-22-125852.txt

## Key facts
- Listing & Compliance Notices
  Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: December 9, 2022, TransCode Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between October 27, 2022 through December 8, 2022, the Company’s common stock had not maintained a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter does not result in the immediate delisting of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465922125852/0001104659-22-125852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.